Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) at the 19th Annual CTAD conference in Boston, November 16-19, 2026. The presentations cover preliminary baseline characteristics of enrolled participants plus qualitative data on patient and care-partner experiences — not new efficacy or safety results.
Key figures
- Drug Name
- sabirnetug (ACU193)
- Phase Of Trial
- Phase 2
- Topline timing
- late 2026
- Trial enrollment
- 542
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.